Clinical trial disruption continues as pandemic rages on

9 June 2021
research_technology_lab_big

Research from industry analyst GlobalData finds that companies and organizations are continuing to report clinical trial disruptions on account of the ongoing COVID-19 pandemic.

The upset to research and development activities is due to a number of factors, including slower enrollment and suspensions to enrollment, as well as delayed initiation.

Drawing from a survey of key opinion leaders in the pharma industry, researchers found that the primary factor behind the slowdown was slower-than-usual enrollment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical